Immunome
Market cap $2.03B 118.1M shares (10-Q, Nov 4, 2026) × $17.18 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- Varegacestat MAA filingplanned by end of 2026Varegacestat MAA filing, planned by end of 2026, notable
- IM-1335 IND filinglate 2026IM-1335 IND filing, late 2026, notable
- IM-1021 ADC interimDec 14, 2026IM-1021 ADC interim, Dec 14, 2026, notable
- IM-1617 ADC interim2027IM-1617 ADC interim, 2027, notable
- Varegacestat FDA decisionApr 28, 2027Varegacestat FDA decision, Apr 28, 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (9 active programs)
IM-1021
IM-3050
IM-1617
IM-1340
IM-1335
Technology platforms
HC74
Proprietary topoisomerase 1 inhibitor (TOP1i) payload platform supporting ADC development across oncology targets; paired with proprietary optimized linkers to enable next-generation ADC pipeline
Targets: TOP1
Capital (as filed)
- Cash
- $213M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $249M Sep 30, 2026
- Operating cash flow
- −$60.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $425M cash per the update of Oct 5, 2026 — the company's own words as read there, not the filed figure
Offering documents (2)
- 2026-11-09 S-3ASR · Shelf registration up to $200M aggregate
- 2026-11-09 S-3ASR · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (4)
- 2026-11-05 UPDATE: Immunome (IMNM) - The Canary Sings ★ Distilled Pro
- 2026-10-06 UPDATE: Immunome (IMNM) - Buying Out the Landlord 🔒 Paid
- 2026-08-12 UPDATE: Immunome (IMNM) - The Clock Is Set, and It Runs Long 🔒 Paid
- 2026-06-22 Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (4 calls)
Every verdict Biotech Distilled has published on Immunome, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-06-22 Watch Immunome, Inc. (IMNM) — Scientific Deep Dive for Varegacestat and the HC74 ADC Pipeline Positive Phase 3 and NDA filed, but rich ~$1.8B EV after a +200% run, low-teen BMS royalty drag, 80% dose-reduction safety tab, EcoR1 trimming, and second-mover launch against Merck KGaA-backed incumbent warrant waiting for a better entry or launch traction evidence.
- 2026-08-12 Watch UPDATE: Immunome (IMNM) - The Clock Is Set, and It Runs Long FDA accepted the NDA with an April 2027 PDUFA (standard review), valuation expanded ~39% on procedural news, burn running above model, and the second-mover discount deserves to widen with delay — still waiting for a better entry or IM-1021 data.
- 2026-10-06 Watch UPDATE: Immunome (IMNM) - Buying Out the Landlord BMS royalty and milestone obligations eliminated for ~$113M (cash + stock), improving per-share economics and M&A appeal, but a confirmed upgrade still needs the IM-1021 lymphoma readout; accumulating on weakness worth considering, especially on BMS resale dips.
- 2026-11-05 Speculative buy speculative UPDATE: Immunome (IMNM) - The Canary Sings IM-1021 delivered first human evidence of HC74 platform efficacy (53% ORR in B-NHL, 64% in DLBCL after T-cell therapies), BMS royalty already eliminated, stock below pre-run-up levels — the gating event arrived and the entry is better, but n=19 with no durability data and 44% grade ≥3 neutropenia keep it speculative pending December ASH update.
- Long call · opened Nov 5, 2026 at $17.91 · -4.0% vs XBI -2.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (12 quotes from 5 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“IM-1335, a solid tumor ADC, is in preclinical development with an anticipated IND submission in late 2026.”
matched to IM-1021 (ROR1 ADC) · interim data / matched to IM-1335 · regulatory submission -
“We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027.”
matched to Varegacestat · regulatory decision
-
-
-
““We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA.”
matched to Varegacestat · regulatory decision
-
-
-
“IND-enabling work for IM-1335 is ongoing and we expect to submit an IND for this program to the FDA in late 2026.”
matched to IM-1335 · regulatory submission -
“IND-enabling work for IM-1340 is ongoing and we expect to submit an IND for this program to the FDA in mid-2026.”
matched to IM-1340 · regulatory submission -
“We submitted a new drug application, or NDA, for varegacestat in April 2026, which has been accepted by the U.S. Food and Drug Administration, or FDA, and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of April 28, 2027.”
matched to Varegacestat · regulatory decision
-
-
-
“Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.”
matched to IM-1335 · regulatory submission -
““For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch.”
matched to Varegacestat · regulatory decision
-
-
-
“IND-enabling work for IM-1335 is ongoing and we expect to submit an IND for this program to the FDA in late 2026.”
matched to IM-1335 · regulatory submission -
“Preclinical ADC Pipeline : Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.”
matched to IM-1335 · regulatory submission -
“IND-enabling work for IM-1340 is ongoing and we expect to submit an IND for this program to the FDA in mid-2026.”
matched to IM-1340 · regulatory submission -
““For varegacestat, the presentation of detailed Phase 3 RINGSIDE data at ASCO and subsequent FDA acceptance of our NDA with a PDUFA target action date of April 28, 2027 represent important steps toward a potential approval and launch.”
matched to Varegacestat · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (22)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026S-3ASRAutomatic shelf registration
- Nov 9, 2026S-3ASRAutomatic shelf registration
- Nov 9, 2026ReleaseImmunome Reports Third Quarter 2026 Financial Results and Provides Business Updatevia aggregator
- Nov 9, 20268-KCurrent report: results of operations · EX-99.1
- Nov 9, 202610-QQuarterly report
- Nov 4, 2026ReleaseImmunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026via aggregator→ BD updateIM-1021 delivers a 53% ORR (64% in DLBCL) across all dose levels in heavily pretreated B-NHL patients — the first human proof that the HC74 TOP1i payload engine works, the exact catalyst I said could convert optionality into an asset.
- Nov 2, 2026ReleaseImmunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conferencevia aggregator
- Oct 30, 2026ReleaseImmunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumorsvia aggregatorBD extracted 1 program update from this document → IMNM pipeline
- Oct 26, 2026ReleaseImmunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026BD extracted 1 program update from this document → IMNM pipeline
- Oct 5, 20268-KCurrent report: material agreement, unregistered sale of equity→ BD updateImmunome quietly bought out the entire BMS royalty and milestone burden on varegacestat — paying $20M cash + ~4.4M shares — and now owns the patents outright, transforming the drug's commercial economics ahead of the April 2027 PDUFA date.
- Sep 30, 2026ReleaseImmunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumorsvia aggregator
- Sep 2, 2026ReleaseImmunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Aug 11, 2026ReleaseImmunome Reports Second Quarter 2026 Financial Results and Provides Business UpdateBD extracted 1 program update from this document → IMNM pipeline
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jun 12, 20268-KCurrent report: shareholder vote
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 24, 2026DEFA14AProxy soliciting material
- Apr 24, 2026DEF 14AProxy statement
- Mar 3, 20268-KCurrent report: results of operations · EX-99.1
- Mar 3, 202610-KAnnual report
12 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Oct 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 11, 2026S-8Employee plan registration
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 3, 2026S-8Employee plan registration